VLS Valneva SE

VALNEVA - Declaration of shares and voting rights - July 31, 2022

VALNEVA - Declaration of shares and voting rights - July 31, 2022

VALNEVA

Declaration of shares and voting rights

July 31, 2022

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment A

Declaration date: August 4, 2022

  

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the changeDate on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



117,351,857









    including:
  • 117,331,343 ordinary shares with a par value of €0.15 each; and
  • 20,514 preferred shares convertible into ordinary shares, with a par value of €0.15 each
139,903,366Sale of 1,540 shares with double voting rights



 



Double voting rights granted on 5,275 ordinary shares
July 4, 2022



 



July 3, 17 and 27, 2022
139,779,044

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
04/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
 PRESS RELEASE

Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provid...

Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the yearChief Executive Officer’s contract renewed for a further three-year term, ensuring continuity in leadership Lyon (France), February 19, 2026 – (Nasdaq: VALN; Euronext Paris...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch